Anastasia Antoniadou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7656050/publications.pdf

Version: 2024-02-01

101 papers

5,216 citations

147801 31 h-index 91884 69 g-index

103 all docs

103 docs citations

103 times ranked

9924 citing authors

#	Article	IF	CITATIONS
1	Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host and Microbe, 2020, 27, 992-1000.e3.	11.0	1,746
2	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	9.1	400
3	An Outbreak of Infection due to βâ€Lactamase <i>Klebsiella pneumoniae</i> Carbapenemase 2–Producing <i>K. pneumoniae</i> in a Greek University Hospital: Molecular Characterization, Epidemiology, and Outcomes. Clinical Infectious Diseases, 2010, 50, 364-373.	5.8	251
4	Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. Journal of Antimicrobial Chemotherapy, 2007, 59, 786-790.	3.0	224
5	Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 2012, 56, 4241-4249.	3.2	201
6	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
7	Acinetobacter baumannii: a universal threat to public health?. International Journal of Antimicrobial Agents, 2008, 32, 106-119.	2.5	185
8	Candidemia in a Tertiary Care Cancer Center. Medicine (United States), 2003, 82, 309-321.	1.0	113
9	Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. Journal of Infection, 2009, 58, 273-284.	3.3	95
10	In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek Hospitals. Antimicrobial Agents and Chemotherapy, 2006, 50, 3166-3169.	3.2	91
11	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	5.8	83
12	Association of <scp>COVID</scp> â€19 with impaired endothelial glycocalyx, vascular function andÂmyocardial deformation 4 months after infection. European Journal of Heart Failure, 2021, 23, 1916-1926.	7.1	81
13	The Association Between Colonization With Carbapenemase-Producing Enterobacteriaceae and Overall ICU Mortality. Critical Care Medicine, 2015, 43, 1170-1177.	0.9	77
14	Increasing Prevalence of HIV $\hat{\mathbf{a}}$ Subtype A in Greece: Estimating Epidemic History and Origin. Journal of Infectious Diseases, 2007, 196, 1167-1176.	4.0	68
15	Evaluation of a rapid antigen detection test in the diagnosis of streptococcal pharyngitis in children and its impact on antibiotic prescription. Journal of Antimicrobial Chemotherapy, 2008, 62, 1407-1412.	3.0	62
16	Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. International Journal of Antimicrobial Agents, 2016, 47, 335-339.	2.5	61
17	Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrobial Agents and Chemotherapy, 2000, 44, 3264-3271.	3.2	56
18	Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece. International Journal of Antimicrobial Agents, 2007, 30, 360-365.	2.5	56

#	Article	IF	CITATIONS
19	Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection. Intensive Care Medicine, 2008, 34, 2169-75.	8.2	55
20	Association of Highly Active Antiretroviral Therapy With Increased Arterial Stiffness in Patients Infected With Human Immunodeficiency Virus. American Journal of Hypertension, 2009, 22, 828-834.	2.0	49
21	ANTIPSEUDOMONAL ANTIBIOTICS. Medical Clinics of North America, 2001, 85, 19-42.	2.5	46
22	Evaluation of CHROMagarâ,, KPC for the detection of carbapenemase-producing Enterobacteriaceae in rectal surveillance cultures. International Journal of Antimicrobial Agents, 2011, 37, 124-128.	2.5	46
23	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	6.0	46
24	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. PLoS ONE, 2020, 15, e0243025.	2.5	45
25	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	1.9	41
26	HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clinical Science, 2008, 115, 189-196.	4.3	39
27	Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms, 2020, 8, 1885.	3.6	39
28	Combination therapy for extensively-drug resistant gram-negative bacteria. Expert Review of Anti-Infective Therapy, 2017, 15, 1123-1140.	4.4	37
29	In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1143-1150.	2.9	37
30	INFECTIOUS COMPLICATIONS OF FEBRILE LEUKOPENIA. Infectious Disease Clinics of North America, 2001, 15, 457-482.	5.1	34
31	Fever of Unknown Origin in Febrile Leukopenia. Infectious Disease Clinics of North America, 2007, 21, 1055-1090.	5.1	32
32	Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Eurosurveillance, 2020, 25, .	7.0	31
33	Association of Tollâ€Like Receptor 4 Asp299Gly and Thr399lle Polymorphisms with Increased Infection Risk in Patients with Advanced HIVâ€1 Infection. Clinical Infectious Diseases, 2010, 51, 242-247.	5.8	29
34	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	5.8	29
35	Myocardial work and vascular dysfunction are partially improved at 12 months after <scp>COVID</scp> â€19 infection. European Journal of Heart Failure, 2022, 24, 727-729.	7.1	28
36	Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. International Journal of Antimicrobial Agents, 2009, 33, 137-142.	2.5	27

#	Article	IF	CITATIONS
37	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 219-224.	2.9	26
38	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. PLoS ONE, 2020, 15, e0230730.	2.5	24
39	Promoting prudent use of antibiotics: the experience from a multifaceted regional campaign in Greece. BMC Public Health, 2014, 14, 866.	2.9	23
40	Implementation of surgical site infection surveillance in low- and middle-income countries: A position statement for the International Society for Infectious Diseases. International Journal of Infectious Diseases, 2020, 100, 123-131.	3.3	23
41	Reduction of Environmental Contamination With Multidrug-Resistant Bacteria by Copper-Alloy Coating of Surfaces in a Highly Endemic Setting. Infection Control and Hospital Epidemiology, 2017, 38, 765-771.	1.8	19
42	Transmission Dynamics of HIV-1 Drug Resistance among Treatment-NaÃ-ve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health. Genes, 2017, 8, 322.	2.4	19
43	Does a bed rail system of alcohol-based handrub antiseptic improve compliance of health care workers with hand hygiene? Results from a pilot study. American Journal of Infection Control, 2009, 37, 160-163.	2.3	17
44	Impact of a hospital-wide antibiotic restriction policy program on the resistance rates of nosocomial Gram-negative bacteria. Scandinavian Journal of Infectious Diseases, 2013, 45, 438-445.	1.5	16
45	Angiotensinâ€convertingâ€enzyme insertion/deletion polymorphism, ACE activity, and COVIDâ€19: A rather controversial hypothesis. A caseâ€control study. Journal of Medical Virology, 2022, 94, 1050-1059.	5.0	14
46	Status of combination therapy for refractory mycoses. Current Opinion in Infectious Diseases, 2003, 16, 539-545.	3.1	13
47	Comparison of direct antimicrobial susceptibility testing methods for rapid analysis of bronchial secretion samples in ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2011, 38, 130-134.	2.5	13
48	In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Journal of Antimicrobial Chemotherapy, 2020, 75, 2164-2172.	3.0	13
49	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. Aids, 2019, 33, 1645-1655.	2.2	12
50	Gastrointestinal Carriage of Vancomycin-Resistant Enterococci and Carbapenem-Resistant Gram-Negative Bacteria in an Endemic Setting: Prevalence, Risk Factors, and Outcomes. Frontiers in Public Health, 2020, 8, 55.	2.7	12
51	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. Microorganisms, 2021, 9, 806.	3.6	12
52	The Effect of Monitoring of Antibiotic use on Decreasing Antibiotic Resistance in the Hospital. Novartis Foundation Symposium, 1997, 207, 76-92.	1.1	12
53	Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals. AIDS Research and Human Retroviruses, 2013, 29, 461-469.	1.1	10
54	Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgB1	/Owerlock	≀ 1 0 of 50 57 1

#	Article	IF	CITATIONS
55	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clinical Infectious Diseases, 2020, 71, 2599-2607.	5.8	10
56	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	4.4	10
57	Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1376-1383.	1.2	9
58	Dissemination of International Clone II <i>Acinetobacter baumannii</i> Strains Coproducing OXA-23 Carbapenemase and 16S rRNA Methylase ArmA in Athens, Greece. Microbial Drug Resistance, 2020, 26, 9-13.	2.0	9
59	Low birth weight and head circumference as potential biomarkers of sensorineural hearing loss in asymptomatic congenitally CMV-infected infants. Journal of Clinical Virology, 2020, 129, 104471.	3.1	9
60	Microcirculatory Vascular Dysfunction in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy. Microcirculation, 2010, 17, 303-310.	1.8	8
61	A Nationwide Study about the Dispersal Patterns of the Predominant HIV-1 Subtypes A1 and B in Greece: Inference of the Molecular Transmission Clusters. Viruses, 2020, 12, 1183.	3.3	8
62	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100Âcells/Â μ L. Journal of the International AIDS Society, 2021, 24, e25726.	3.0	8
63	Variation in Genes of \hat{l}^2 -glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	2.0	7
64	Coronavirus disease 2019 pandemic in Greece, February 26 – May 3, 2020: The first wave. Travel Medicine and Infectious Disease, 2021, 41, 102051.	3.0	7
65	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofab588.	0.9	7
66	Eosinophilia Associated With Olanzapine. Journal of Clinical Psychopharmacology, 2016, 36, 180-181.	1.4	6
67	Low-Dose Cotrimoxazole Administered in Hematopoietic Stem Cell Transplant Recipients as Prophylaxis for Pneumocystis jirovecii Pneumonia Is Effective in Prevention of Infection due to Nocardia. Biology of Blood and Marrow Transplantation, 2019, 25, e298-e299.	2.0	6
68	Risk of congenital cytomegalovirus infection in children born to women with IgG avidity in the grey zone during first trimester of pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 2025-2029.	1.5	6
69	Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection. Cytokine, 2012, 60, 104-107.	3.2	5
70	The impact of an antimicrobial cycling strategy for febrile neutropenia in a haematology unit. Journal of Chemotherapy, 2013, 25, 279-285.	1.5	5
71	Characterization of 16S rRNA methylase genes in Enterobacterales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015–2016. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 111-121.	2.9	5
72	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. Viruses, 2021, 13, 1844.	3.3	5

#	Article	IF	CITATIONS
7 3	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	3.0	5
74	Two successfully treated cases of Staphylococcus lugdunensis endocarditis. Diagnostic Microbiology and Infectious Disease, 2010, 68, 445-448.	1.8	4
75	Risk factors for community-associated methicillin-resistant Staphylococcus aureus colonisation in a large metropolitan area in Greece: An epidemiological study using two case definitions. Journal of Global Antimicrobial Resistance, 2014, 2, 27-33.	2.2	4
76	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. PLoS ONE, 2018, 13, e0203601.	2.5	4
77	Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece. In Vivo, 2020, 34, 3039-3045.	1.3	4
78	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infectious Diseases, 2021, 21, 309.	2.9	4
79	Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates. Infection, Genetics and Evolution, 2021, 91, 104799.	2.3	4
80	Vaccination Hesitancy among Health-Care-Workers in Academic Hospitals Is Associated with a 12-Fold Increase in the Risk of COVID-19 Infection: A Nine-Month Greek Cohort Study. Viruses, 2022, 14, 26.	3.3	4
81	Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 511-513.	2.4	3
82	HIV continuum of care: bridging cross-sectional and longitudinal analyses. Aids, 2022, 36, 583-591.	2.2	3
83	Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece. World Journal of Nephrology, 2022, 11, 58-72.	2.0	3
84	Genetic Evolution of Human Immunodeficiency Virus Type 1 in Two Spouses Responding Successfully to Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2003, 19, 65-71.	1.1	2
85	Ovarian hyperstimulation syndrome complicated by severe communityâ€acquired pneumonia due to methicillinâ€resistant Staphylococcus aureus positive for Pantonâ€Valentine leukocidin. Journal of Obstetrics and Gynaecology Research, 2012, 38, 476-478.	1.3	2
86	Prescription of antibiotics and knowledge about antibiotic costs among physicians working in tertiary-care hospitals. Journal of Chemotherapy, 2014, 26, 375-378.	1.5	2
87	Reliability, validity and psychometric properties of the Greek translation of the posttraumatic stress disorder scale. Mental Illness, 2017, 9, 6832.	0.8	2
88	Earlier treatment initiation is associated with a decreased number of HIV-1 subtype A1 transmissions in Greece. Sexually Transmitted Infections, 2021, 97, 232-237.	1.9	2
89	Dating the Origin and Estimating the Transmission Rates of the Major HIV-1 Clusters in Greece: Evidence about the Earliest Subtype A1 Epidemic in Europe. Viruses, 2022, 14, 101.	3.3	2
90	Mapping frailty in people living with <scp>HIV</scp> : A nationwide study in Greece. HIV Medicine, 2023, 24, 170-179.	2.2	2

#	Article	IF	CITATIONS
91	InÂvivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections. Clinical Microbiology and Infection, 2022, 28, 73-78.	6.0	1
92	An exploration of the quality of life of people living with HIV in Greece: Challenges and opportunities. PLoS ONE, 2022, 17, e0266962.	2.5	1
93	COLONIZATION SURVEILLANCE PREDICTS MICROBIAL ETIOLOGY OF INFECTION IN THE CRITICALLY ILL. Chest, 2005, 128, 143S.	0.8	0
94	Patterns of drug resistance among newly diagnosed HIV-1 infected patients in Greece during the last decade: the crucial role of transmission networks. Journal of the International AIDS Society, 2014, 17, 19742.	3.0	0
95	The role of fluoroquinolones in the therapy and prophylaxis of neutropenic patients with cancer. Milestones in Drug Therapy, 2003, , 219-238.	0.1	O
96	Fever of Unknown Origin in Febrile Leukopenia. Infectious Disease and Therapy, 2007, , 35-58.	0.0	0
97	Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 4498-4498.	1.4	0
98	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. , 2020, 15, e0243025.		0
99	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. , 2020, 15, e0243025.		0
100	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19., 2020, 15, e0243025.		0
101	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19., 2020, 15, e0243025.		O